Phase I Trial of Doxorubicin and Alvocidib (Flavopiridol; NCI Supplied Agent, NSC 649890) in the Treatment of Metastatic Sarcoma
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Alvocidib (Primary) ; Doxorubicin
- Indications Soft tissue sarcoma
- Focus Adverse reactions
- 18 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jul 2012 Planned End Date changed from 1 Jun 2010 to 1 Jan 2100 as reported by ClinicalTrials.gov (NCT01645488).